AstraZeneca (AZN) Rating Lowered to Neutral at Bryan, Garnier & Co

Bryan, Garnier & Co lowered shares of AstraZeneca (LON:AZN) to a neutral rating in a research report report published on Thursday morning.

Several other brokerages have also issued reports on AZN. Barclays reaffirmed an overweight rating and issued a GBX 6,600 ($86.24) target price (up previously from GBX 6,500 ($84.93)) on shares of AstraZeneca in a research note on Friday, August 10th. HSBC set a GBX 4,840 ($63.24) target price on shares of AstraZeneca and gave the company a sell rating in a research note on Wednesday, August 15th. Shore Capital reaffirmed a hold rating on shares of AstraZeneca in a research note on Wednesday, August 15th. Credit Suisse Group reaffirmed an outperform rating on shares of AstraZeneca in a research note on Tuesday, October 23rd. Finally, Liberum Capital reaffirmed a hold rating on shares of AstraZeneca in a research note on Tuesday, October 23rd. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of Hold and an average price target of GBX 5,831.89 ($76.20).

Shares of LON AZN traded up GBX 79 ($1.03) during mid-day trading on Thursday, hitting GBX 6,172 ($80.65). The company’s stock had a trading volume of 1,976,706 shares, compared to its average volume of 2,310,000. AstraZeneca has a one year low of GBX 4,260 ($55.66) and a one year high of GBX 5,520 ($72.13).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: Technical Analysis of Stocks, How Can It Help

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply